Sanofi SAN-1.79%decrease; red down pointing triangle said two bleeding disorder treatments for both chronic and acute conditions have been approved in China, expanding its hematology offerings in the ...

Investing.com -- Sanofi has received approval for two bleeding disorder treatments in China, expanding its hematology portfolio in the country. The French pharmaceutical company announced Thursday ...

Sanofi said two bleeding disorder treatments for both chronic and acute conditions have been approved in China, expanding its hematology offerings in the country. The French pharmaceutical company ...

About The Study: Cryopreserved platelets did not meet the predefined threshold for noninferiority in hemostatic effectiveness at 24 hours after intensive care unit admission. Additional predefined end ...

Abnormal Uterine Bleeding (AUB) is a common gynaecological concern, but one that often goes ignored until it disrupts daily life. It refers to any change in your menstrual volume, duration, or ...

Experiencing blood streaks after a sneeze can be alarming, but it's often due to common issues like dry air, allergies, or forceful sneezes irritating delicate nasal vessels. Understanding these ...

In September 2025, the US Food and Drug Administration (FDA) approved Rhapsido ® (remibrutinib), an oral small molecule kinase inhibitor, for the treatment of chronic spontaneous urticaria (CSU) in ...

$157M Series C adds leading life science investors including Sofinnova Partners, a large long-only global asset management company, a large global sovereign wealth fund, and Avoro Capital Advisors ...

Sutacimig is being developed as the first-ever prophylactic treatment for Glanzmann thrombasthenia (GT), a serious and potentially life-threatening bleeding disorder affecting patients worldwide. The ...

Bleeding in ET can range from minor mucocutaneous events to severe hemorrhages, with gastrointestinal bleeding being most common. The JAK2 V617F variant increases bleeding and thrombosis risk, ...

Researchers at Penn Medicine are pursuing a new mRNA-based therapy to explore the underlying causes of abnormal uterine bleeding and develop a treatment. Kathleen O’Neill — a professor of obstetrics ...